Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
Carlos Doti, VP US Medical Affairs of Oncology at AstraZeneca, shared a post on LinkedIn:
“ASH25 showcased AstraZeneca’s continued growth in hematology.
A decade ago, we presented one abstract. In 2025, we presented 65 abstracts, including:
- 15 oral presentations
- spanning 8 medicines
- 11 diseases
What makes this milestone meaningful isn’t just the science, but how our focus has evolved.
Our responsibility is clear: to help patients have the best quality of life.
As I hear directly from patients, what they want most is freedom from continuous treatment and the chance to return to what truly matters.
Thank you to Mary Caffrey for the opportunity to share these insights and discuss how AstraZeneca is advancing the future of blood cancer care. I encourage you to read the full piece in AJMC – The American Journal of Managed Care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 18, 2026, 16:47Sophia Delicou: Importance of Assessing Hemoglobin Functional Capacity Rather Than Total Levels
-
Feb 18, 2026, 16:32Cheng-Hock Toh: 5 Steps to Transform Transfusion Practice
-
Feb 18, 2026, 16:26Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
-
Feb 18, 2026, 16:24Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
-
Feb 18, 2026, 16:23Hamad Abbasi: Why are Coronary Stents so Expensive?
-
Feb 18, 2026, 16:05Shiny K. Kajal: Routine vs Massive Transfusion Protocol
-
Feb 18, 2026, 16:03Maria Farid: Successful Consultative Hematology and Transfusion Medicine Workshop at PKLI
-
Feb 18, 2026, 15:59Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?
-
Feb 18, 2026, 15:55Amelia Carro Hevia: Defining the Future of Cardiovascular Medicine at ACC 2026